Mostrando 10 resultados de: 11
Filtros aplicados
Publisher
Bionatura(3)
BMC Cancer(1)
BMC Infectious Diseases(1)
Biotecnologia Aplicada(1)
Electronic Journal of Biotechnology(1)
Clinical Research & Clinical Trials Challenges and Perspectives
OtherAbstract:Palabras claves:Autores:Thelvia I. Ramos GómezFuentes:scopusCIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
ArticleAbstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, wPalabras claves:apoptosis, Cancer targeted therapy, Casein kinase 2Autores:Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusActive immunotherapy in lung cancer, new therapeutic options
OtherAbstract:Palabras claves:Autores:Thelvia I. Ramos GómezFuentes:scopusAdditives and protein-DNA combinations modulate the humoral immune response elicited by a hepatitis C virus core-encoding plasmid in mice
ArticleAbstract: Humoral and cellular immune responses are currently induced against hepatitis C virus (HCV) core folPalabras claves:Core, DNA immunization, Hepatitis C virusAutores:Alvarez-Lajonchere L., Dueñas-Carrera S., Morales J., Pichardo D., Thelvia I. Ramos Gómez, Viña A.Fuentes:scopusAdjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study
ArticleAbstract: Background: High antibiotic resistance is described in atypical Mycobacteriosis, mainly by MycobactePalabras claves:Autores:Bello-Rivero I., Fernández-Olivera N., García-García I., González-Méndez L., Jiménez-Madrigal G., López-Saura P.A., Martínez-Sánchez G., Milanés-Virelles M.T., Rodríguez-Acosta C., Sánchez-de la Osa R.B., Santos-Herrera Y., Thelvia I. Ramos Gómez, Valdés-Quintana M., Valenzuela-Silva C.M.Fuentes:googlescopusAdvances in Clinical Research in Ecuador
ArticleAbstract: Ecuador is undergoing a process of clinical research development and strengthening. At the turn of tPalabras claves:clinical research, clinical trials, Economic development, ECUADOR, PharmaceuticalAutores:Castro K.A., Luis Santiago Escalante, Santiago Nelson Vispo, Thelvia I. Ramos GómezFuentes:scopusForms and methods for interferon’s encapsulation
ReviewAbstract: Interferons (IFNs) are cytokines involved in the immune response that act on innate and adaptive immPalabras claves:Antiproliferative, antiviral, Drug delivery system, Encapsulate IFNs, formulation, IFN-α, IFN-β, IFN-γ, Immunomodulator, interferons, Liposomes, Microparticles, Nanoparticles, Pegylation, Polymeric micellesAutores:Leandro Santiago Padilla, Parra N.C., Santana S.P., Santiago Nelson Vispo, Thelvia I. Ramos Gómez, Toledo Alonso J.R., Villacis-Aguirre C.A.Fuentes:googlescopusEstablishment of a production process for a novel vaccine candidate against Lawsonia intracellularis
ArticleAbstract: Background: Lawsonia intracellularis remains a problem for the swine industry worldwide. Previously,Palabras claves:fed-batch culture, Immune response, LAWSONIA INTRACELLULARIS, Proliferative enteropathy, Recombinant vaccineAutores:Acosta J., Altamirano C., González A., Gutiérrez N., Montesino R., Ramos E., S. Salazar, Sanchez O., Thelvia I. Ramos Gómez, Toledo J.R.Fuentes:scopusLOX-1 in cardiovascular diseases, future therapeutic perspectives
ArticleAbstract: The low-density oxidized lipoprotein lectin-1 (LOX-1) receptor, also known as OLR-1, is a scavengerPalabras claves:atherosclerosis, dyslipidemia, endothelial dysfunction, LOX-1 lectin-like OxLDL receptor 1, Oxidized low-density lipoprotein, Soluble LOX-1Autores:Alonso J.R.T., Thelvia I. Ramos GómezFuentes:scopusSafety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
ArticleAbstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwidPalabras claves:Autores:Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopus